Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab

NCT00184366 is registered in ClinicalTrials.gov with Norwegian University of Science and Technology as lead sponsor.

NCT NCT00184366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00184366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab
Lead sponsor
Norwegian University of Science and Technology
Phase
Observational
Overall status
Terminated
Start date
May 31, 2005
Completion date
July 31, 2008
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis